Jump to content

Niceritrol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by BD2412 (talk | contribs) at 20:22, 25 August 2022 (Fixing links to disambiguation pages, replaced: niacinniacin). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Niceritrol
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 3-[(pyridin-3-yl)carbonyloxy]-2,2-bis({[(pyridin-3-yl)carbonyloxy]methyl})propyl pyridine-3-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.025.017 Edit this at Wikidata
Chemical and physical data
FormulaC29H24N4O8
Molar mass556.531 g·mol−1
3D model (JSmol)
  • C1=CC(=CN=C1)C(=O)OCC(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4
  • InChI=1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2 ☒N
  • Key:KUEUWHJGRZKESU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Niceritrol is a niacin derivative used as a hypolipidemic agent. It is an ester of pentaerythritol and nicotinic acid, has general properties similar to those of nicotinic acid (Nicotinamide), to which it is slowly hydrolysed. Niceritrol has been used as a lipid regulating drug in hyperlipidaemias and as a vasodilator in the treatment of peripheral vascular disease.[1][2]

References

  1. ^ Owada A, Suda S, Hata T (April 2003). "Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial". The American Journal of Medicine. 114 (5): 347–53. doi:10.1016/s0002-9343(02)01567-x. PMID 12714122.
  2. ^ Truven Health Analytics Inc. (May 8, 2008). "Niceritrol". Micromedexsolutions.com. Retrieved December 14, 2014.